Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tan5-7 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Tongji Medical College
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Tan5-7 CAR-T cells are an experimental tandem bispecific chimeric antigen receptor T-cell (CAR-T) therapy designed to simultaneously target two T-cell surface antigens: CD5 and CD7. The construct utilizes fully human heavy chain variable (FHVH) antibody domains for both targets, integrated into a tandem CAR structure with a 4-1BB costimulatory domain and a CD3ζ signaling domain (BBz). To prevent fratricide (self-killing) during production and after infusion, CRISPR/Cas9-based knockout of the endogenous CD5 and CD7 genes is performed in the T cells prior to lentiviral transduction. This dual-targeting approach aims to overcome antigen escape and improve efficacy in relapsed or refractory T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell leukemia/lymphoma. Additionally, it has been explored as a conditioning regimen alternative to enable allogeneic hematopoietic stem cell transplantation (HSCT). The research originates from academic institutions in China, including Tongji Medical College.
- Other names
- CD5/CD7 tandem CAR-T cellsCD5/CD7 bispecific CAR-T cells
02
Targets
CD5 (T-cell surface glycoprotein CD5)CD7 (CD7 antigen)
Beyond the preview
Go deeper on Tan5-7 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tan5-7 CAR-T cells.